Answers are grounded in this paper and cite their sources.
Platelets, traditionally recognized as core components of the coagulation system, have emerged as critical regulators in the multistep progression of colorectal cancer (CRC) beyond their hemostatic functions. Accumulating evidence demonstrates that platelets orchestrate a multidimensional network to promote CRC initiation, proliferation, invasion, metastasis, and immune escape through direct interactions with tumor cells, modulation of the tumor microenvironment, and regulation of angiogenic processes. Two key platelet surface molecules, P-selectin (CD62P) and C-type lectin-like receptor-2 (CLEC- 2), serve as central hubs in these pro-tumorigenic cascades: CD62P mediates platelet-tumor cell aggregation, extravasation, and immunosuppressive macrophage polarization, while CLEC-2 interacts with its ligand podoplanin (PDPN) to drive platelet activation, tumor cell epithelial-mesenchymal transition, and cancer-associated thrombosis. In-depth research into their mechanisms of action is of great significance for the development of targeted therapeutic drugs for colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: